Merck Says Phase 3 KEYFORM-007 Trial Of Fixed-dose Combination Of Favezelimab And Keytruda (Pembrolizumab) Did Not Meet Its Primary Endpoint Of Overall Survival For Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer
Portfolio Pulse from Benzinga Newsdesk
Merck announced that its Phase 3 KEYFORM-007 trial, testing a fixed-dose combination of Favezelimab and Keytruda (Pembrolizumab), did not meet the primary endpoint of overall survival in patients with previously treated PD-L1 positive microsatellite stable metastatic colorectal cancer.
September 25, 2024 | 10:47 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Merck's Phase 3 trial for a combination therapy involving Keytruda did not achieve its primary endpoint, potentially impacting investor sentiment negatively.
The failure to meet the primary endpoint in a Phase 3 trial is significant as it may affect the future prospects of the drug combination, leading to potential negative sentiment among investors. Keytruda is a major product for Merck, and setbacks in its development can impact stock prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100